>

Moncef Slaoui - GlaxoSmithKline PLC Chairman

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:6em;padding-top: 0px;;'>G</div>
GSK -- USA Stock  

0.592 Dividend

  Chairman
Dr. Moncef Slaoui is no longer as Chairman Global Vaccines, Executive Director of GlaxoSmithKline PLC, effective 31 March 2017. He joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead RD in 2006. He was given overall responsibility for GSKs Oncology Business in 2010 for GSK Vaccines in 2011 and for all Global Franchises in 2012. Moncef has advised the US Presidents Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology Research until January 2011. He has a PhD in Molecular Biology and Immunology from Universit Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. External appointments Moncef is a member of the Biotechnology Industry Organization Board in the US and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. Moncef serves as a NonExecutive Director for the International AIDS Vaccine Initiative .
Age: 55  Chairman Since 2014  Ph.D    
(44) 20 8047 7807  www.gsk.com
Slaoui joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was also given overall responsibility for GSK?s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. He has a PhD in Molecular Biology and Immunology from Universit? Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. He is a member of the PhRMA and the Biotechnology Industry Organization boards in the USA and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee

Management Efficiency

The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Enrico VanniNovartis AG
2013
Paul BisaroAllergan Plc
2016
Jorge MesquitaJohnson Johnson
2016
Sandra PetersonJohnson Johnson
2017
Ian ReadPfizer
2018
Joerg ReinhardtNovartis AG
2013
Brenton SaundersAllergan Plc
2016
Alex KrauerNovartis AG
N/A
Thibaut MongonJohnson Johnson
2018
Joaquin DuatoJohnson Johnson
2018
John MartinGilead Sciences
N/A
Kenneth FrazierMerck Company
2011
Paulus StoffelsJohnson Johnson
2018
Jennifer TaubertJohnson Johnson
2018
John LechleiterEli Lilly And Company
2016
Ashley McEvoyJohnson Johnson
2018
Giovanni CaforioBristol Myers Squibb Company
2017
Daniel VasellaNovartis AG
N/A
Leif JohanssonAstrazeneca PLC
2012
Alex GorskyJohnson Johnson
2012
Lamberto AndreottiBristol Myers Squibb Company
2015

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 95,490 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive DirectorView
Lynn Elsenhans, Independent Non-Executive DirectorView
Luke Miels, President - Global PharmaceuticalsView
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive DirectorView
Daniel Podolsky, Non-Executive Independent DirectorView
Emma Walmsley, Chief Executive Officer, Executive DirectorView
Luc Debruyne, President - Global VaccinesView
Andrew Witty, CEO, Executive DirectorView
Brian McNamara, Chief Executive Officer - GSK Consumer HealthcareView
Roy Anderson, Non-Executive Independent DirectorView
Philip Hampton, Independent Non-Executive DirectorView
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Vivienne Cox, Non-Executive Independent DirectorView
Bill Louv, Senior Vice President - Core Business ServicesView
Roger Connor, President - Global Manufacturing & SupplyView
Abbas Hussain, President Global PharmaceuticalsView
Phil Thomson, Senior Vice President - Global CommunicationsView
Judy Lewent, Non-Executive Independent DirectorView
Hans Wijers, Independent Non-Executive DirectorView
Stephanie Burns, Non-Executive Independent DirectorView
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Urs Rohner, Non-Executive Independent DirectorView
Marvinder Banga, Senior Non-Executive Independent DirectorView
Deryck Maughan, Senior Independent Non-Executive DirectorView
Jesse Goodman, Non-Executive Independent DirectorView
Laurie Glimcher, Non-Executive Independent DirectorView
Nick Hirons, Senior Vice President - Global Ethics and ComplianceView
James Ford, Senior Vice President General CounselView
Victoria Whyte, Company SecretaryView
Daniel Troy, Sr. VP and General CounselView
Shah Hussain, President - Europe, Japan & EMAPView
Manvinder Banga, Non-Executive DirectorView
David Redfern, Chief Strategy OfficerView
Patrick Vallance, President - Pharmaceuticals R&DView
Stacey Cartwright, Non-Executive Independent DirectorView
Regis Simard, President - Pharmaceutical Supply ChainView
Jonathan Symonds, Independent Non-Executive Chairman of the BoardView
Iain Mackay, Chief Financial Officer, Executive DirectorView
Karenann Terrell, Chief Digital & Technology OfficerView
Claire Thomas, Senior Vice President - Human ResourcesView

Stock Performance Indicators

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.